I cannot provide an adequate gene function summary for DST (dystonin) based on the provided PubMed abstracts. The three abstracts supplied discuss diabetes management and biomarkers in clinical trials, with no content related to DST, cytoskeletal organization, axonal transport, or the associated diseases (epidermolysis bullosa simplex 3 and hereditary sensory and autonomic neuropathy 6). To generate an evidence-based summary grounded in the provided literature as required, I would need PubMed abstracts that actually address DST's molecular mechanisms, its role in microtubule or hemidesmosome organization, and its involvement in sensory neuron function or skin barrier maintenance. The current set of abstracts is insufficient to support any factual claims about this gene's biology or clinical significance.